Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05244694 · ClinicalTrials.gov registry record · Early Phase 1

Impact of Insulin on Sympathetic Nervous System-mediated Peripheral Vasoconstriction

A Early Phase 1 study, sponsored by University of Missouri-Columbia.

Completed
Registry status
Early Phase 1
Development phase
28
Enrollment target

NCT05244694 is a Early Phase 1 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 28 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05244694, a Early Phase 1 study, has completed, sponsored by University of Missouri-Columbia.

COMPLETED
Registry status
Early Phase 1
Development phase
28 participants
Enrollment target

Study Summary

The purpose of this project is to determine if hyperinsulinemia attenuates sympathetic nervous system-mediated vasoconstriction in the human leg.

Interventions

  • DRUG Insulin

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2020-08-06
Est. Completion 2021-06-25
Phase Early Phase 1

Sponsor

University of Missouri-Columbia

291 total trials

What the Registry Record Tells You About NCT05244694

The ClinicalTrials.gov registry entry for NCT05244694 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Insulin is the first listed.

NCT05244694 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05244694 about?

NCT05244694 is a clinical study titled "Impact of Insulin on Sympathetic Nervous System-mediated Peripheral Vasoconstriction". The purpose of this project is to determine if hyperinsulinemia attenuates sympathetic nervous system-mediated vasoconstriction in the human leg.

What is the current status of trial NCT05244694?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2020-08-06. Estimated completion is 2021-06-25.

What interventions are being tested in trial NCT05244694?

The interventions under investigation include: Insulin (DRUG).

Who is sponsoring clinical trial NCT05244694?

This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.